Salim Syed is ranked #1487 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Salim Syed (Mizuho Securities) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Salim Syed's stock ratings?

About 53% of Salim's ratings were profitable over a one-year hold, with an average return of +9.0% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Salim Syed

MIZU

Salim Syed

Mizuho Securities

Wall Street Analyst

★★★☆☆

#1487

on 13Foresight · ranked by our own returns

53%

Success Rate

+9.0%

Average Return

19 of 36 calls profitable · -2.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 53% of Salim Syed's ratings turned a profit when each position was held for 1 year — averaging +9.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

51 Buy 6 Hold 0 Sell

Salim's Stock Coverage 30 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
BBIO BridgeBio Pharma	Jun 15, 2026	BUY	Strong Buy +38.3% avg upside 34 analysts	$96.00 44.91% Upside	-0.9%
AMGN Amgen	Jun 15, 2026	HOLD	Buy -11.6% avg upside 57 analysts	$303.00 10.20% Downside	-0.8%
BIIB Biogen	Jun 12, 2026	BUY	Strong Buy +25.1% avg upside 51 analysts	$221.00 12.41% Upside	-0.7%
WVE Wave Life Sciences	Jun 12, 2026	BUY	Strong Buy +261.8% avg upside 28 analysts	$27.00 338.24% Upside	+4.9%
ASMB Assembly Biosciences	Jun 12, 2026	BUY	Strong Buy +38.6% avg upside 10 analysts	$45.00 84.14% Upside	·
GILD Gilead Sciences	Jun 12, 2026	BUY	Strong Buy -4.8% avg upside 66 analysts	$170.00 37.38% Upside	-0.8%
IPSC Century Therapeutics	Jun 10, 2026	BUY	Strong Buy +132.9% avg upside 11 analysts	$8.00 249.31% Upside	+8.9%
AUTL Autolus Therapeutics	Jun 10, 2026	BUY	Strong Buy +605.8% avg upside 16 analysts	$10.00 562.21% Upside	·
ELVN Enliven Therapeutics	Jun 02, 2026	BUY	Strong Buy +7.2% avg upside 14 analysts	$62.00 37.57% Upside	+22.3%
PCVX Vaxcyte	Jun 02, 2026	BUY	Strong Buy +96.3% avg upside 15 analysts	$163.00 216.97% Upside	+3.9%
NKTX Nkarta	Mar 31, 2026	BUY	Strong Buy +554.9% avg upside 15 analysts	$12.00 319.51% Upside	+25.1%
SNDX Syndax Pharmaceuticals	Mar 30, 2026	BUY	Strong Buy +88.7% avg upside 27 analysts	$43.00 126.26% Upside	-18.5%
MAZE Maze Therapeutics, Inc.	Mar 30, 2026	BUY	Strong Buy +145.3% avg upside 12 analysts	$97.00 277.78% Upside	-14.4%
ATRA Atara Biotherapeutics	Mar 30, 2026	BUY	Buy +79.8% avg upside 18 analysts	$18.00 78.69% Upside	+123.8%
KURA Kura Oncology	Mar 24, 2026	BUY	Strong Buy +162.8% avg upside 26 analysts	$25.00 151.85% Upside	+18.6%
CYTK Cytokinetics	Mar 18, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	$100.00 27.02% Upside	+27.0%
INCY Incyte	Dec 08, 2025	BUY	Buy +1.0% avg upside 47 analysts	$121.00 23.28% Upside	+2.4%
FATE Fate Therapeutics	Nov 14, 2025	BUY	Buy +492.3% avg upside 31 analysts	$8.00 282.81% Upside	+106.2%
RCUS Arcus Biosciences	Aug 18, 2025	BUY	Strong Buy +38.0% avg upside 20 analysts	$45.00 85.11% Upside	+130.8%
CRSP Crispr Therapeutics AG	May 20, 2025	BUY	Buy +39.7% avg upside 41 analysts	$85.00 57.16% Upside	+23.7%
IOVA Iovance Biotherapeutics	May 09, 2025	BUY	Strong Buy +225.4% avg upside 24 analysts	$10.00 155.75% Upside	+106.9%
MRK Merck & Company	Nov 22, 2024	HOLD	Strong Buy +10.7% avg upside 43 analysts	—	+1.5%
XNCR Xencor	Nov 22, 2024	HOLD	Strong Buy +159.5% avg upside 27 analysts	—	-36.5%
PFE Pfizer	May 28, 2024	BUY	Buy +34.1% avg upside 45 analysts	$53.00 110.30% Upside	-12.6%
SLE Super League Enterprise	Mar 25, 2024	BUY	Strong Buy +492.5% avg upside 8 analysts	$25.00 678.75% Upside	-84.1%
CHRS Coherus Biosciences	Jun 16, 2023	HOLD	Buy +748.3% avg upside 18 analysts	—	-59.1%
AI C3ai	Mar 06, 2023	BUY	Sell +111.5% avg upside 24 analysts	$21.00 103.80% Upside	+18.6%
BMRN BioMarin Pharmaceutical	Nov 03, 2022	BUY	Strong Buy +72.7% avg upside 52 analysts	$23.00 57.92% Downside	-6.2%
PFS Provident Financial Services	Aug 04, 2022	BUY	Strong Buy +34.4% avg upside 16 analysts	$25.00 9.96% Upside	-20.4%
ORN Orion Group Holdings	Jul 02, 2019	BUY	Strong Buy -24.2% avg upside 15 analysts	$7.10 55.29% Downside	+7.5%

🔒 25 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Salim Syed — Frequently Asked Questions

How accurate are Salim Syed's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Salim's ratings were profitable over a one-year hold, with an average return of +9.0% per rating, or -2.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Salim ranked on 13Foresight?

Salim Syed is currently ranked #1487 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Salim cover?

Salim most recently has ratings on BBIO, AMGN, BIIB, WVE, ASMB, GILD, IPSC, AUTL, ELVN, PCVX, NKTX, SNDX and 18 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!